Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in Obesity or Overweight with Type 2 Diabetes (Japan, J2A-MC-GZP2)
jRCT2051250035Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of orforglipron in obesity, Overweight and type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in hemoglobin A1c (HbA1c). Started Jun 2025; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2051250035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250035.